5-year failure-free survival.意思是：5年无失败（无差错/无故障-根据上下文决定）成活率/存活率。
ARMS is an independent predictor of poor prognosis, with failure-free survival of approximately 65% and 20% for localized and metastatic disease, respectively. Although the PAX3 and PAX7 tumors show similar prognosis for localized disease, the PAX3 tumors have a dismal prognosis when metastatic, ...
求翻译:The failure-free survival and OS in the SC-EPOCH-RR (short-course REPOCH with a double dose of rituximab) patients were 100% and 90%,respectively是什么意思?待解决 悬赏分:1 - 离问题结束还有 The failure-free survival and OS in the SC-EPOCH-RR (short-course REPOCH with a double...
Purpose: To evaluate failure-free survival (FFS) for brachytherapy (BT) alone compared to external beam radiotherapy (EBRT) alone for Stage T1-2 Nx-No Mo patients over the same time period by a single community-based practice in the prostate-specific antigen (PSA) era. Materials and Methods...
The failure-free survival of the Durata lead was significantly better than that of the Riata lead (P 0.0001) and similar to that of the Sprint Quattro (P 0.94). The 7 Fr. Riata ST lead had better survival compared with the 8 Fr. Riata lead (P 0.050) and comparable survival with ...
The durability of PSA failure-free survival from 5 years to 13 years following radiotherapy in patients with localized prostate cancer Author links open overlay panelT.I Yock, H.K Thakral, A.L Zietman, W.U ShipleyShow more Add to Mendeley Share Cite...
The free-from-failure survival was 49.2% at 10 years, being 64.7% for patients achieving complete remission and 92.4% for long-term complete responders. Although an increased number of second malignant neoplasms may occur in patients treated for Hodgkin’s disease, the high risk of early relapse...
The 3-year locoregional failure-free survival (LRFFS) and overall survival (OS) rates for all patients were 50.7%, and 53.2%, respectively. On multivariate analysis, the preoperative carcinoembryonic antigen (CEA) level, resection margin, histologic grade, T stage, and N stage were significant ...
The free-from-failure survival was 49.2% at 10 years, being 64.7% for patients achieving complete remission and 92.4% for long-term complete responders. Although an increased number of second malignant neoplasms may occur in patients treated for Hodgkin's disease, the high risk of early relapse...
Long-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according to a brief report published online Sept. 27 in JAMA Cardiology to coincide with t